Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Crinetics Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CRNX
Nasdaq
8731
https://www.crinetics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 11th, 2024 8:05 pm
Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
- Mar 26th, 2024 11:01 pm
Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
- Mar 22nd, 2024 11:02 pm
Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
- Mar 22nd, 2024 11:02 pm
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
- Mar 21st, 2024 2:01 pm
Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
- Mar 21st, 2024 6:32 am
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
- Mar 20th, 2024 9:14 am
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
- Mar 19th, 2024 8:48 pm
Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
- Mar 19th, 2024 8:03 pm
UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study
- Mar 19th, 2024 10:16 am
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
- Mar 19th, 2024 10:00 am
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Mar 12th, 2024 8:05 pm
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mar 11th, 2024 8:05 pm
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 1:57 pm
Crinetics Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
- Mar 1st, 2024 10:37 am
Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ...
- Feb 28th, 2024 9:36 pm
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Feb 28th, 2024 9:05 pm
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Feb 28th, 2024 1:00 pm
Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc
- Feb 15th, 2024 8:14 am
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Feb 14th, 2024 9:05 pm
Scroll